Minerva Neurosciences Seeks to Double Authorized Shares, Boost Equity Plan

TL;DR

**NERV is gearing up for massive dilution with a proposed doubling of authorized shares and a significant boost to its equity plan; tread carefully.**

AI Summary

Minerva Neurosciences, Inc. (NERV) is holding its 2025 Annual Meeting on December 22, 2025, virtually, to address several critical proposals impacting its corporate structure and equity. Key proposals include the election of two Class II directors, Fouzia Laghrissi-Thode and Inderjit Kaul, to serve until the 2028 Annual Meeting. The company seeks to double its authorized common stock from 125,000,000 shares to 250,000,000 shares, a significant increase that could facilitate future capital raises or strategic transactions. Additionally, NERV is requesting approval for the issuance of common stock upon conversion of its Series A Convertible Voting Preferred Stock, including shares from warrants, to comply with Nasdaq Listing Rules, specifically Rule 5635(d). The company also plans to increase the aggregate number of shares authorized under its 2013 Equity Incentive Plan by 12,500,000 shares, which could impact dilution for existing shareholders. Stockholders will also cast an advisory vote on executive compensation and ratify Deloitte & Touche LLP as the independent auditor for fiscal year 2025.

Why It Matters

Minerva Neurosciences' proposals have significant implications for investors, potentially leading to substantial dilution if the authorized share increase to 250,000,000 shares and the 12,500,000 share increase for the 2013 Equity Incentive Plan are approved. The approval of Series A Preferred Stock conversion is crucial for compliance with Nasdaq Listing Rules, ensuring the company maintains its listing status. These changes could enable NERV to raise capital more easily, fund ongoing research and development in a competitive neuroscience market, or pursue strategic partnerships, but at the cost of potential shareholder value erosion through dilution. Employees could benefit from increased equity incentives, aligning their interests with company performance.

Risk Assessment

Risk Level: high — The proposal to increase authorized common stock from 125,000,000 shares to 250,000,000 shares, combined with an additional 12,500,000 shares for the 2013 Equity Incentive Plan, presents a high risk of significant future dilution for existing shareholders. This substantial increase in potential share count could depress per-share value and voting power, especially given the current 6,993,406 shares of Common Stock outstanding.

Analyst Insight

Investors should carefully evaluate the potential for dilution from the proposed increase in authorized shares and the equity incentive plan. Consider voting against Proposals 2 and 4 if you are concerned about the immediate and long-term impact on your ownership stake and per-share value. Engage with investor relations for clarity on the specific use of the increased authorized shares.

Key Numbers

• 250,000,000 shares — Proposed total authorized common stock (Increase from 125,000,000 shares, representing a 100% increase)
• 12,500,000 shares — Increase in shares for 2013 Equity Incentive Plan (Additional shares authorized for employee compensation)
• 125,000,000 shares — Current total authorized common stock (Baseline before proposed amendment)
• 6,993,406 shares — Common Stock outstanding (As of Record Date October 23, 2025, entitled to vote)
• 1,391,674 shares — Series A Preferred Stock outstanding (as-converted) (As of Record Date October 23, 2025, entitled to vote on an as-converted basis)
• 9.99% — Maximum Percentage (Beneficial ownership limit for Series A Preferred Stock conversion)
• 19.9% — Cap on Series A Preferred Stock voting (Percentage of outstanding Common Stock for voting calculation prior to Proposal 3 approval)
• December 22, 2025 — Annual Meeting Date (Date of the virtual Annual Meeting)
• October 23, 2025 — Record Date (Date for determining stockholders entitled to vote)

Key Players & Entities

• Minerva Neurosciences, Inc. (company) — Registrant for DEF 14A filing
• Fouzia Laghrissi-Thode (person) — Nominee for Class II Director
• Inderjit Kaul (person) — Nominee for Class II Director
• Nasdaq Listing Rules (regulator) — Compliance requirement for Series A Preferred Stock conversion
• Rule 5635(d) (regulator) — Specific Nasdaq rule for Series A Preferred Stock conversion
• Deloitte & Touche LLP (company) — Independent registered public accounting firm
• Frederick Ahlholm (person) — Chief Financial Officer
• Computershare Trust Company, N.A. (company) — Transfer agent
• SEC (regulator) — Securities and Exchange Commission

FAQ

Industry Context

Minerva Neurosciences operates in the biopharmaceutical sector, focusing on developing treatments for central nervous system disorders. This industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on substantial capital raises to fund clinical trials and operations, making stock authorization proposals critical for future flexibility.

Regulatory Implications

The proposed increase in authorized shares and the issuance of stock upon conversion of Series A Preferred Stock are directly linked to compliance with Nasdaq Listing Rule 5635(d). Failure to secure shareholder approval for these items could jeopardize Minerva's listing on the Nasdaq exchange.

What Investors Should Do

1. Review the implications of doubling authorized common stock.
2. Evaluate the proposed increase in the 2013 Equity Incentive Plan.
3. Understand the necessity of approving stock issuance for Series A Preferred Stock conversion.
4. Vote on the election of directors Fouzia Laghrissi-Thode and Inderjit Kaul.

Key Dates

• 2025-12-22: 2025 Annual Meeting of Stockholders — Stockholders will vote on critical proposals including director elections, stock authorization, and executive compensation.
• 2025-11-24: Mailing of Proxy Materials — Informs stockholders of the upcoming meeting and proposals, enabling them to cast their votes.
• 2025-10-23: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of shareholders, including proposals to be voted on. (This document contains the information being analyzed for Minerva Neurosciences' upcoming annual meeting.)

Class II Directors

Directors whose terms expire in a particular year, typically part of a staggered board structure. (Two Class II directors are up for election at the 2025 Annual Meeting.)

Authorized Common Stock

The maximum number of shares of common stock that a corporation is legally permitted to issue, as specified in its charter. (Minerva is seeking to double its authorized common stock, which could impact future financing and dilution.)

Series A Convertible Voting Preferred Stock

A class of preferred stock that can be converted into common stock and carries voting rights. (Approval is needed for the issuance of common stock upon conversion of this preferred stock to comply with Nasdaq rules.)

2013 Equity Incentive Plan

A plan established by the company to grant stock options, restricted stock units, or other equity awards to employees and directors. (The company proposes to increase the number of shares available under this plan, potentially increasing dilution.)

Nasdaq Listing Rules

Rules set by the Nasdaq stock exchange that listed companies must adhere to regarding corporate governance, financial reporting, and other matters. (A specific rule (5635(d)) requires shareholder approval for certain stock issuances, which Minerva is seeking.)

Year-Over-Year Comparison

This analysis is based on the 2025 DEF 14A filing. Information for comparison with a prior year's filing (e.g., 2024 DEF 14A) regarding financial metrics like revenue, net income, or margins is not available within the provided text. The current filing focuses on proposals for the upcoming annual meeting, including significant changes to the company's capital structure and equity plans.

Key Financial Figures

• $0.0001 — r of authorized shares of common stock, $0.0001 par value per share (the "Common Stock"

Filing Documents

• d925225ddef14a.htm (DEF 14A) — 818KB
• g925225dsp073.jpg (GRAPHIC) — 158KB
• g925225dsp074.jpg (GRAPHIC) — 131KB
• g925225dsp075.jpg (GRAPHIC) — 147KB
• g925225dsp076.jpg (GRAPHIC) — 131KB
• g925225g57n01.jpg (GRAPHIC) — 87KB
• g925225g57n02.jpg (GRAPHIC) — 89KB
• 0001193125-25-293674.txt ( ) — 3424KB
• nerv-20241231.xsd (EX-101.SCH) — 11KB
• d925225ddef14a_htm.xml (XML) — 104KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 46

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 48 Summary Compensation Table 48 Outstanding Equity Awards at Fiscal Year-End 49 Arrangements with Our Executive Officers 50 DIRECTOR COMPENSATION 58 TRANSACTIONS WITH RELATED PERSONS RELATED PERSON TRANSACTIONS POLICY AND PROCEDURES 60 Certain Relationships and Related Person Transactions 60 EQUITY COMPENSATION PLAN INFORMATION 64 HOUSEHOLDING OF PROXY MATERIALS 65 OTHER MATTERS 66 APPENDIX A: Certificate of Amendment to the Amended and Restated Certificate of Incorporation A-1 APPENDIX B: Amended and Restated 2013 Equity Incentive Plan B-1 i Table of Contents MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington, MA 01803 PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS To Be Held on December 22, 2025 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why am I receiving these materials? We have sent you these proxy materials because the Board of Directors (the "Board") of Minerva Neurosciences, Inc. (sometimes referred to as the "Company" or "Minerva") is soliciting your proxy to vote at the 2025 Annual Meeting of Stockholders (the "Annual Meeting"), including at any adjournments or postponements of the meeting. You are invited to attend the annual meeting online to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy over the phone or through the internet. We intend to first mail these proxy materials on or about November 24, 2025 to all stockholders of record entitled to vote at the Annual Meeting. Why are you holding a virtual Annual Meeting? We believe that hosting a virtual meeting is in the best interest of the Company and its stockholders and enables increased stockholder attendance and participation because stockholders can participate f

View Full Filing

View this DEF 14A filing on SEC EDGAR